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1. INTRODUCTION {#ajmga38603-sec-0002}
===============

Rubinstein--Taybi syndrome (RSTS) is a congenital disorder characterized by intellectual disability, unusual behavior, postnatal growth retardation, and multiple congenital anomalies, especially of the face and distal limbs (Rubinstein & Taybi, [1963](#ajmga38603-bib-0046){ref-type="ref"}). The birth prevalence of RSTS is 1:100,000 to 1:125,000 (Hennekam, [2006](#ajmga38603-bib-0021){ref-type="ref"}). RSTS is caused by a heterozygous mutation in the gene encoding the transcriptional co‐activator CREB‐binding protein (*CREBBP*) on chromosome 16p13.3 in about 60% of affected individuals (Petrij et al., [1995](#ajmga38603-bib-0041){ref-type="ref"}), a submicroscopic deletion at 16p13.3 in about 10% of individuals (Hennekam, [2006](#ajmga38603-bib-0021){ref-type="ref"}), or a mutation of the gene E1A binding protein p300 (*EP300*) on chromosome 22q13.2 in about 5--10% of individuals (Fergelot et al., [2016](#ajmga38603-bib-0020){ref-type="ref"}; Roelfsema et al., [2005](#ajmga38603-bib-0043){ref-type="ref"}). In the remaining RSTS individuals, no specific genetic alterations can be detected and the diagnosis is based on the combination of clinical manifestations only. Most mutations occur de novo although vertical transmission of mutations has been described (Hennekam, [2006](#ajmga38603-bib-0021){ref-type="ref"}).

CREBBP and EP300 are closely related proteins belonging to the K‐acetyltransferase‐3 (KAT3) family of histone/protein lysine acetyltransferases, which serve as transcriptional co‐activators for a large number of DNA‐binding transcription factors that mediate multiple signaling and developmental pathways (Wang et al., [2010](#ajmga38603-bib-0065){ref-type="ref"}). Mutations in *CREBBP* and *EP300* have been demonstrated in various benign and malignant tumors, including in up to 40% of diffuse large cell B‐cell lymphoma (DLBCL) and follicular lymphoma cases (Lohr et al., [2012](#ajmga38603-bib-0031){ref-type="ref"}; Morin et al., [2011](#ajmga38603-bib-0037){ref-type="ref"}; Pasqualucci et al., [2011](#ajmga38603-bib-0040){ref-type="ref"}; Zhang et al., [2011](#ajmga38603-bib-0072){ref-type="ref"}). A specific type of acute myeloid leukemia is associated with a chromosomal translocation involving *CREBBP* (Rozman et al., [2004](#ajmga38603-bib-0045){ref-type="ref"}).

Various benign and malignant tumors have been described in RSTS individuals. In 1989, Siraganian, Rubinstein, and Miller ([1989](#ajmga38603-bib-0054){ref-type="ref"}) reported a series of 574 RSTS individuals in whom 22 tumors were detected in 19 persons (3.3%). Nine were malignant, 13 were benign, and 79% occurred under the age of 20. Miller and Rubinstein ([1995](#ajmga38603-bib-0036){ref-type="ref"}) expanded the above series and reported 36 tumors in 725 RSTS individuals (5%). Tumors of the central nervous system and of hematological origin were relatively frequently reported (12 and 6 of 36 neoplasms, respectively) and two individuals with pilomatricomas were noted. For both studies, molecular confirmation of RSTS was not yet possible at the time of publication, preventing genotype--phenotype studies. Genotype--phenotype studies have not been performed in subsequent reports either. The data in these series were composed of cases reported in literature and cases reported to Dr Jack Rubinstein (Miller & Rubinstein, [1995](#ajmga38603-bib-0036){ref-type="ref"}; Siraganian et al., [1989](#ajmga38603-bib-0054){ref-type="ref"}).

Individuals with RSTS are prone to develop excessive scar tissue (keloids). In 24% of RSTS individuals, itching keloids develop during puberty and adulthood (van de Kar et al., [2014](#ajmga38603-bib-0062){ref-type="ref"}). It has been suggested that, similarly to other neoplastic processes, keloids in RSTS individuals may also be a result of deregulated proliferation of fibroblasts and thereby may serve as a model to study in those individuals the earliest oncogenic changes (Siraganian et al., [1989](#ajmga38603-bib-0054){ref-type="ref"}; van de Kar et al., [2014](#ajmga38603-bib-0062){ref-type="ref"}).

Here, we report the results of a study on the incidence of benign and malignant tumors and on possible genotype--phenotype correlations in a nation‐wide, population‐based study covering all known RSTS individuals in the Netherlands between 1986 and 2015. The results are compared to an overview of all reported tumors in individuals with RSTS in the literature to date.

2. MATERIALS AND METHODS {#ajmga38603-sec-0003}
========================

2.1. Study population {#ajmga38603-sec-0004}
---------------------

In the Netherlands, individuals diagnosed with RSTS are identified with an almost complete coverage, as most families with a child with RSTS become member of the dedicated support group (Stichting RSTS) and until 2010 all molecular diagnostics for RSTS have been performed in a single laboratory (Leiden University Medical Centre). Furthermore, affected individuals and their families are almost invariably seen in the expertise clinic for individuals with RSTS led one of the authors (RCH). All families known to either of these sources were contacted and informed consent was obtained for all individuals with RSTS in the present study. The characteristics of all participants, including results of physical exams and presence of keloids, had been obtained during various, typically repeated exams of all individuals by one of the authors (RCH). The study, including linkage of name, sex, and date of birth via a "Trusted Third Partner" to PALGA, has been approved by the Medical Ethical Committee of the Academic Medical Centre in Amsterdam (NL33011.018.11).

2.2. PALGA database search for benign and malignant tumors in individuals with RSTS {#ajmga38603-sec-0005}
-----------------------------------------------------------------------------------

Since 1985, all pathology reports are centrally archived in the nationwide network and registry of histopathology and cytopathology in the Netherlands (PALGA), with a nationwide coverage of all academic and non‐academic hospitals since 1990 (Casparie et al., [2007](#ajmga38603-bib-0015){ref-type="ref"}). Standardized coding allows for comprehensive searches for specific and detailed diagnoses and patient cohorts, while still compliant to current privacy regulations.

Using the name, sex, and date of birth, all histopathological and cytological pathology registrations of all known RSTS individuals were retrieved from the PALGA database. To identify relevant diagnoses that may not be diagnosed by histopathological or cytological examination, and therefore may not be registered in PALGA (e.g., acute leukemia), the database of the Netherlands Cancer Registry was searched using the same strategy. Medical data, including results of physical exams and presence of keloids, were retrieved from the files of one of the authors (RCH). Benign and malignant tumors were defined as described by Willis ([1952](#ajmga38603-bib-0068){ref-type="ref"}).

All relevant pathology slides were retrieved from the original pathology laboratories and reviewed by two experienced pathologists (PW, DDJ). Presence of keloid lesions was assessed predominantly on clinical grounds, as described elsewhere (van de Kar et al., [2014](#ajmga38603-bib-0062){ref-type="ref"}) and histologically confirmed if reported in the PALGA database.

All available genotype data for both *CREBBP* and *EP300* mutations were obtained from the original diagnostic laboratories. All molecular studies had been performed as part of routine clinical work‐up, no additional molecular studies were performed specifically for the present study. Only individuals with a proven variant in *CREBBP* or *EP300* were included in analysis.

2.3. Literature review of benign and malignant tumors in individuals with RSTS {#ajmga38603-sec-0006}
------------------------------------------------------------------------------

A PubMed search was performed using the queries "Rubinstein--Taybi syndrome," "Rubinstein--Taybi syndrome," "Rubinstein--Taybi," and "Rubinstein--Taybi" as to cover all publications on RSTS. All retrieved publications, including individual case reports and case series, were scanned for tumors. The references in the publications were hand‐searched for further publications. Publications in other languages than English were excluded. There were no other exclusion criteria.

3. RESULTS {#ajmga38603-sec-0007}
==========

3.1. Benign and malignant tumors in individuals with RSTS in the Netherlands {#ajmga38603-sec-0008}
----------------------------------------------------------------------------

Between 1986 and 2015, 87 persons (37 male, 50 female), have been clinically diagnosed with RSTS in the Netherlands. Characteristics of the affected individuals with known mutation data are listed in Table [1](#ajmga38603-tbl-0001){ref-type="table-wrap"}; further details of all RSTS individuals are provided in Supplementary Table S1.

###### 

Overview of tumors detected between 1986 and 2015 in individuals with molecularly confirmed RSTS in the Netherlands

  Age at time of present study           Sex   Neoplasm                                       Age at histopathological diagnosis   Keloid   Affected gene
  -------------------------------------- ----- ---------------------------------------------- ------------------------------------ -------- ---------------
  **Nonsense and frameshift mutation**                                                                                                      
  6                                      M                                                                                         −        *CREBBP*
  8                                      F     Pilomatricoma                                  4                                    \+       *CREBBP*
  8                                      F                                                                                         −        *CREBBP*
  8                                      F                                                                                         −        *CREBBP*
  10                                     M                                                                                         −        *EP300*
  12                                     F                                                                                         \+       *CREBBP*
  15                                     M                                                                                         n/a      *CREBBP*
  21                                     M     Hemangioma                                     15                                   −        *CREBBP*
  23                                     M                                                                                         \+       *CREBBP*
  27                                     F                                                                                         n/a      *CREBBP*
  31                                     M                                                                                         \+       *CREBBP*
  40                                     F                                                                                         \+       *CREBBP*
  46^†^                                  M                                                                                         \+       *CREBBP*
  56                                     M                                                                                         n/a      *CREBBP*
  57^†^                                  M     DLBCL                                          57                                   −        *CREBBP*
  59^†^                                  F                                                                                         \+       *CREBBP*
  59                                     M                                                                                         −        *CREBBP*
  65^†^                                  F     Meningioma Hemangioma                          41 42                                −        *CREBBP*
  **Deletions and duplications**                                                                                                            
  2                                      M                                                                                         n/a      *CREBBP*
  15                                     M                                                                                         −        *CREBBP*
  16                                     F     Pilomatricoma                                  5                                    −        *CREBBP*
  16                                     F                                                                                         −        *CREBBP*
  19                                     M                                                                                         −        *CREBBP*
  22                                     M     Pilomatricoma                                  2                                    −        *CREBBP*
  24                                     F     Pilomatricoma                                  9                                    \+       *CREBBP*
  30                                     M     Pilomatricoma                                  14                                   \+       *CREBBP*
  30                                     M     Nevus Nevus                                    9 25                                 n/a      *CREBBP*
  30                                     F                                                                                         −        *CREBBP*
  34                                     F     Pilomatricoma Pilomatricoma                    6 15                                 \+       *CREBBP*
  34^†^                                  F     Meningioma Breast carcinoma NSCLC              29 31 34                             −        *CREBBP*
  40                                     F     Pilomatricoma Pilomatricoma                    19 37                                −        *EP300*
  41                                     F                                                                                         n/a      *CREBBP*
  42^†^                                  F     Neuroma Dermatofibroma Meningioma Meningioma   29 32 36 37                          −        *CREBBP*
  43^†^                                  M                                                                                         −        *CREBBP*
  53                                     F     Fibroadenoma of breast Meningioma              38 46                                n/a      *CREBBP*
  **Splice site mutation**                                                                                                                  
  10^†^                                  M     Medulloblastoma                                9                                    −        *CREBBP*
  39                                     M     Pilomatricoma                                  15                                   −        *CREBBP*
  40                                     M                                                                                         −        *CREBBP*
  52                                     F                                                                                         n/a      *CREBBP*
  59^†^                                  M     Colon carcinoma                                58                                   \+       *CREBBP*
  **Missense mutation**                                                                                                                     
  23                                     F                                                                                         −        *EP300*
  46                                     F     HSIL                                           49                                   \+       *CREBBP*
  **Mutation type unknown**                                                                                                                 
  2                                      F                                                                                         −        *EP300*
  21                                     F                                                                                         n/a      *CREBBP*
  30                                     F                                                                                         −        *EP300*

 ^†^, Deceased; N/A, data not available; NSCLC, non‐small cell lung carcinoma; DLBCL, Diffuse large B‐cell lymphoma; HSIL, high grade squamous intra‐epithelial lesion of the cervix.

© 2018 Wiley Periodicals, Inc.

All RSTS diagnoses were confirmed based on clinical criteria by a single observer (RCH). Cytogenetic and/or molecular confirmation for *CREBBP* and *EP300* has been performed only after this had become available in 1993 and 1995, respectively, and if indicated for patient care reasons and genetic counseling of family members. The median age at the time of our study was 31 years (range 2--69 years). At the time of the study 15 individuals were deceased, at a median age of 47.7 years (range 10.4--69.7 years).

For 51/87 clinically diagnosed RSTS individuals, histological and/or cytological assessments were recorded in the PALGA database. In total, 159 histological and cytological reports were retrieved in which 35 neoplastic tumor diagnoses were identified in 26 individuals with a maximum of four per person. All diagnoses were confirmed by review of the relevant pathology slides. Five malignant tumors were found in four persons (medulloblastoma, diffuse large cell B‐cell lymphoma, non‐small cell lung carcinoma, breast carcinoma, and colon carcinoma), and two individuals had a premalignant proliferation (both high‐grade squamous intraepithelial lesion of the cervix). Five meningiomas were found in four persons and 23 other, benign tumors were found in 18 individuals, almost exclusively benign cutaneous tumors. Tumors in molecularly confirmed RSTS individuals are listed in Table [1](#ajmga38603-tbl-0001){ref-type="table-wrap"}, tumors in all RSTS individuals are provided in Supplementary Table S1

Though the percentage of individuals with a malignant tumor was higher in specific age categories (Figure [1](#ajmga38603-fig-0001){ref-type="fig"}), numbers were too small to make a reliable comparison.

![Cumulative incidence of malignant tumors and meningiomas in Dutch individuals with molecularly confirmed RSTS compared to that of the general Dutch population per age cohort. Blue, malignant tumors in the general Dutch population; green, malignant tumors in the Dutch RSTS population; orange, meningiomas in the Dutch RSTS population (Cumulative meningioma incidence is \<0,1% in general Dutch population). Data on general population from [www.cijfersoverkanker.nl](http://www.cijfersoverkanker.nl) (retrieved June, 2017). \[Color figure can be viewed at [wileyonlinelibrary.com](https://wileyonlinelibrary.com)\]](AJMG-176-597-g001){#ajmga38603-fig-0001}

3.2. Review of the literature {#ajmga38603-sec-0009}
-----------------------------

A PubMed search yielded 650 publications since the original report in 1963 (Rubinstein & Taybi, [1963](#ajmga38603-bib-0046){ref-type="ref"}). Fifty‐two papers contained data on additional individuals with RSTS with tumors and together these described 97 benign and malignant tumors in 89 individuals. This means that, including the present study, a total of 132 tumors have been reported in 115 individuals with RSTS. An overview of all reported tumors in RSTS is presented in Table [2](#ajmga38603-tbl-0002){ref-type="table-wrap"}.

###### 

Literature overview of tumors reported in individuals with RSTS (including present study)

  Neoplasm                              Age     Sex   Affected gene   Mutation                   Keloid   Reference
  ------------------------------------- ------- ----- --------------- -------------------------- -------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Neurological**                                                                                        
  Medulloblastoma                       4       M     None found      n/a                        \+       Bartsch et al. ([2005](#ajmga38603-bib-0004){ref-type="ref"})
  Medulloblastoma                       8       M     n/a             n/a                        n/a      Bourdeaut et al. ([2014](#ajmga38603-bib-0009){ref-type="ref"})
  Medulloblastoma                       9       M     *CREBBP*        c.1941+3A\>T               −        Present study
  Medulloblastoma                       8       M     n/a             n/a                        n/a      Evans, Burnell, Campbell, Gattamaneni, and Birch ([1993](#ajmga38603-bib-0018){ref-type="ref"}); Miller and Rubinstein ([1995](#ajmga38603-bib-0036){ref-type="ref"})
  Medulloblastoma                       9       M     n/a             n/a                        n/a      Skousen et al. ([1996](#ajmga38603-bib-0055){ref-type="ref"})
  Medulloblastoma                       9       M     n/a             n/a                        n/a      Miller and Rubinstein ([1995](#ajmga38603-bib-0036){ref-type="ref"})
  Neuroblastoma                         0       M     *CREBBP*        c.605dupC                  n/a      de Kort, Conneman, and Diderich ([2014](#ajmga38603-bib-0017){ref-type="ref"})
  Neuroblastoma                         0       M     n/a             n/a                        n/a      Miller and Rubinstein ([1995](#ajmga38603-bib-0036){ref-type="ref"})
  Neuroblastoma                         3       M     n/a             n/a                        n/a      Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"})
  Neuroblastoma                         7       F     n/a             n/a                        n/a      Ihara, Kuromaru, Takemoto, and Hara ([1999](#ajmga38603-bib-0022){ref-type="ref"})
  Glioma                                n/a     n/a   n/a             n/a                        n/a      Lannering, Marky, and Nordborg ([1990](#ajmga38603-bib-0029){ref-type="ref"})
  Glioma                                2       F     *CREBBP*        c.4134G\>T                 n/a      Bartsch et al. ([2010](#ajmga38603-bib-0003){ref-type="ref"})
  Glioma                                n/a     M     n/a             n/a                        n/a      Lannering et al. ([1990](#ajmga38603-bib-0029){ref-type="ref"})
  Oligodendroglioma                     2       F     n/a             n/a                        n/a      Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"})
  Neurilemmoma                          13      M     n/a             n/a                        \+       Russell, Hoffman, and Bain ([1971](#ajmga38603-bib-0048){ref-type="ref"}); Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"})
  Neuroma                               3       F     *CREBBP*        c.5838_5857dup             n/a      Tornese et al. ([2015](#ajmga38603-bib-0060){ref-type="ref"})
  Neuroma^f^                            29      F     *CREBBP*        Microdeletion 9‐31         −        Present study
  Pheochromocytoma                      10      F     n/a             n/a                        n/a      Bonioli and Bellini ([1992](#ajmga38603-bib-0008){ref-type="ref"}); Miller and Rubinstein ([1995](#ajmga38603-bib-0036){ref-type="ref"})
  Adrenocortical adenoma                22      F     n/a             n/a                        n/a      Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"})
  Pinealoma                             14      M     n/a             n/a                        n/a      Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"})
  Pituitary adenoma                     49      M     n/a             n/a                        n/a      Miller and Rubinstein ([1995](#ajmga38603-bib-0036){ref-type="ref"})
  **Meningioma**                                                                                          
  Meningioma^c^                         29      F     *CREBBP*        Microdeletion              −        Present study
  Meningioma^f^                         36      F     *CREBBP*        Microdeletion 9‐31         −        Present study
  Meningioma^f^                         37      F     *CREBBP*        Microdeletion 9‐31         −        Present study
  Meningioma                            39      F     n/a             n/a                        n/a      Bilir, Bilir, and Wilson ([1990](#ajmga38603-bib-0007){ref-type="ref"})
  Meningioma                            39      F     n/a             n/a                        n/a      Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"})
  Meningioma^b^                         41      F     *CREBBP*        c.1011dupA                 −        Present study
  Meningioma^e^                         46      F     *CREBBP*        Exonic duplication 4‐23    n/a      Present study
  **Hematological**                                                                                       
  Leukemia (ALL)                        0       M     n/a             n/a                        n/a      Shaheed, Khamaiseh, Rifai, and Abomelha ([1999](#ajmga38603-bib-0053){ref-type="ref"})
  Leukemia (ALL)                        2       F     n/a             n/a                        n/a      Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"})
  Leukemia (ALL)                        3       M     n/a             n/a                        n/a      Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"})
  Leukemia (ALL)                        6       F     n/a             n/a                        n/a      Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"})
  Leukemia (AML)                        16      M     n/a             n/a                        n/a      Jonas, Heilbron, and Ablin ([1978](#ajmga38603-bib-0027){ref-type="ref"}); Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"})
  Lymphoma (follicular)                 28      F     *CREBBP*        Microdeletion              n/a      Mar, Digiuseppe, and Dailey ([2016](#ajmga38603-bib-0033){ref-type="ref"})
  Lymphoma (mediastinal)                34      F     *CREBBP*        c.2842C\>T                 \+       Wieczorek et al. ([2009](#ajmga38603-bib-0066){ref-type="ref"})
  Lymphoma (DLBCL)                      57      M     *CREBBP*        c.4837delG                 −        Present study
  Lymphoma (non‐Hodgkin\'s)^l^          33      F     n/a             n/a                        n/a      Miller and Rubinstein ([1995](#ajmga38603-bib-0036){ref-type="ref"})
  Lymphoma (non‐Hodgkin\'s)             24      M     n/a             n/a                        \+       Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"})
  Lymphoma (non‐Hodgkin\'s)^j^          58      F     None found      n/a                        n/a      Bartsch et al. ([2005](#ajmga38603-bib-0004){ref-type="ref"})
  **Genital**                                                                                             
  Embryonal carcinoma                   1       F     n/a             n/a                        n/a      Miller and Rubinstein ([1995](#ajmga38603-bib-0036){ref-type="ref"})
  Ovarian carcinoma (serous)^h^         29      F     n/a             n/a                        n/a      Johannesen, Williams, Miller, and Tuller ([2015](#ajmga38603-bib-0026){ref-type="ref"})
  Endometrium adenocarcinoma^h^         29      F     n/a             n/a                        n/a      Johannesen et al. ([2015](#ajmga38603-bib-0026){ref-type="ref"})
  MGSCST                                14      M     No deletion     n/a                        n/a      Kurosawa, Fukutani, Masuno, Kawame, and Ochiai ([2002](#ajmga38603-bib-0028){ref-type="ref"})
  Seminoma testis                       27      M     n/a             n/a                        n/a      Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"})
  Germ cell tumor testis                0       M     *CREBBP*        c.1824‐1G\>A               n/a      Butler et al. ([2016](#ajmga38603-bib-0012){ref-type="ref"})
  HSIL                                  31      F     n/a             n/a                        −        Present study
  HSIL                                  49      F     *CREBBP*        c.4340C\>T                 \+       Present study
  Cystadenoma (paratubal)               15      F     n/a             n/a                        \+       Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"})
  Leiomyoma uterus                      22      F     n/a             n/a                        n/a      Present study
  Leiomyoma^a^                          48      F     n/a             n/a                        −        Present study
  Dermoid cyst                          5       M     n/a             n/a                        n/a      Bozkirli et al. ([2000](#ajmga38603-bib-0010){ref-type="ref"})
  Teratoma ovary^l^                     22      F     n/a             n/a                        n/a      Miller and Rubinstein ([1995](#ajmga38603-bib-0036){ref-type="ref"})
  **Soft tissue**                                                                                         
  Leiomyosarcoma                        n/a     n/a   n/a             n/a                        n/a      Stevens, Pouncey, and Knowles ([2011](#ajmga38603-bib-0057){ref-type="ref"})
  Leiomyosarcoma omentum                11      M     n/a             n/a                        n/a      Miller and Rubinstein ([1995](#ajmga38603-bib-0036){ref-type="ref"})
  Rhabdomyosarcoma^k^                   4       M     n/a             n/a                        n/a      Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"}); Sobel and Woerner ([1981](#ajmga38603-bib-0056){ref-type="ref"})
  Rhabdomyosarcoma                      5       M     n/a             n/a                        n/a      Miller and Rubinstein ([1995](#ajmga38603-bib-0036){ref-type="ref"}); Ruymann et al. ([1988](#ajmga38603-bib-0049){ref-type="ref"})
  Hemangioendothelioma                  1       F     n/a             n/a                        n/a      Altintas and Cakmakkaya, ([2004](#ajmga38603-bib-0001){ref-type="ref"})
  Granular cell tumor                   22      F     n/a             n/a                        n/a      Burton, Kumar, and Bradford ([1997](#ajmga38603-bib-0011){ref-type="ref"})
  Giant cell tumor                      n/a     n/a   n/a             n/a                        n/a      Stevens et al. ([2011](#ajmga38603-bib-0057){ref-type="ref"})
  Circumscribed storiform collagenoma   8       M     n/a             n/a                        \+       Zavras, Mennonna, Maris, and Vaos ([2016](#ajmga38603-bib-0071){ref-type="ref"})
  Fibrolipoma^a^                        46      F     n/a             n/a                        −        Present study
  Leiomyoma duodenum^k^                 n/a     M     n/a             n/a                        n/a      Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"}); Sobel and Woerner ([1981](#ajmga38603-bib-0056){ref-type="ref"})
  **Other malignant tumors**                                                                              
  Colon cancer^j^                       50      F     None found      n/a                        n/a      Bartsch et al. ([2005](#ajmga38603-bib-0004){ref-type="ref"})
  Colon carcinoma                       58      M     *CREBBP*        c.4561‐2A\>G               \+       Present study
  Thyroid cancer                        n/a     n/a   n/a             n/a                        n/a      Stevens et al. ([2011](#ajmga38603-bib-0057){ref-type="ref"})
  Thyroid cancer^j^                     54      F     None found      n/a                        n/a      Bartsch et al. ([2005](#ajmga38603-bib-0004){ref-type="ref"})
  Lung carcinoma (NSCLC)^c^             34      F     *CREBBP*        Microdeletion              −        Present study
  Hepatoblastoma                        0       F     *CREBBP*        c.4650_4654del             n/a      Milani et al. ([2016](#ajmga38603-bib-0035){ref-type="ref"})
  Renal tumor                           n/a     n/a   n/a             n/a                        n/a      Stevens et al. ([2011](#ajmga38603-bib-0057){ref-type="ref"})
  Odontoma                              7       F     n/a             n/a                        n/a      Felgenhauer ([1973](#ajmga38603-bib-0019){ref-type="ref"}); Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"})
  Parathyroid adenoma                   18      F     n/a             n/a                        n/a      Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"})
  Thymoma                               11      M     n/a             n/a                        n/a      Verhoeven, Tuinier, Kuijpers, Egger, and Brunner ([2010](#ajmga38603-bib-0063){ref-type="ref"})
  **Breast**                                                                                              
  Breast adenocarcinoma^c^              31      F     *CREBBP*        Microdeletion              −        Present study
  Breast cancer                         55      F     *EP300*         c.4066C\>T                 −        Fergelot et al. ([2016](#ajmga38603-bib-0020){ref-type="ref"})
  Breast cancer^j^                      43      F     None found      n/a                        n/a      Bartsch et al. ([2005](#ajmga38603-bib-0004){ref-type="ref"})
  Breast cancer                         n/a     F     n/a             n/a                        n/a      Levitas and Reid ([1998](#ajmga38603-bib-0030){ref-type="ref"})
  Fibroadenoma breast^e^                38      F     *CREBBP*        Exonic duplication 4‐23    n/a      Present study
  **Pilomatricoma**                                                                                       
  Pilomatricoma                         2       M     *CREBBP*        Microdeletion              −        Present study
  Pilomatricoma                         4       F     *CREBBP*        c.1318C\>T                 \+       Present study
  Pilomatricoma                         4       F     No deletion     n/a                        −        Masuno et al. ([1998](#ajmga38603-bib-0034){ref-type="ref"})
  Pilomatricoma (multiple)              4--20   F     n/a             n/a                        n/a      Bayle et al. ([2004](#ajmga38603-bib-0006){ref-type="ref"})
  Pilomatricoma                         5       F     *CREBBP*        Microdeletion 1‐4          −        Present study
  Pilomatricoma                         5       M     No deletion     n/a                        −        Masuno et al. ([1998](#ajmga38603-bib-0034){ref-type="ref"})
  Pilomatricoma^g^                      6       F     *CREBBP*        c.2199delG                 n/a      Yoo et al. ([2015](#ajmga38603-bib-0070){ref-type="ref"})
  Pilomatricoma (multiple)              6,15    F     *CREBBP*        Microdeletion 1‐31         \+       Present study
  Pilomatricoma                         8       F     *EP300*         c.1948delA                 n/a      Sellars, Sullivan, and Schaefer ([2016](#ajmga38603-bib-0052){ref-type="ref"})
  Pilomatricoma                         9       F     *CREBBP*        Microdeletion 1‐31         \+       Present study
  Pilomatricoma                         10      F     No deletion     n/a                        \+       Masuno et al. ([1998](#ajmga38603-bib-0034){ref-type="ref"})
  Pilomatricoma (multiple)              12      F     *CREBBP*        c.5837dupC                 n/a      Rokunohe, Nakano, Akasaka, Toyomaki, and Sawamura ([2016](#ajmga38603-bib-0044){ref-type="ref"})
  Pilomatricoma (multiple)              12      F     n/a             n/a                        n/a      Cambiaghi, Ermacora, Brusasco, Canzi, & Caputo ([1994](#ajmga38603-bib-0013){ref-type="ref"}); Miller and Rubinstein ([1995](#ajmga38603-bib-0036){ref-type="ref"})
  Pilomatricoma                         12      F     *CREBBP*        t(2;16)(p13.3;p13.3)       −        Imaizumi and Kuroki ([1991](#ajmga38603-bib-0024){ref-type="ref"}); Masuno et al. ([1998](#ajmga38603-bib-0034){ref-type="ref"})
  Pilomatricoma                         12      M     n/a             n/a                        n/a      Miller and Rubinstein ([1995](#ajmga38603-bib-0036){ref-type="ref"})
  Pilomatricoma                         14      M     *CREBBP*        Exonic duplication 12‐19   \+       Present study
  Pilomatricoma                         15      M     *CREBBP*        c.4394 +--4A\>C            −        Present study
  Pilomatricoma (multiple)              19,37   F     *EP300*         Microdeletion 24‐29        −        Present study
  Pilomatricoma                         49      F     *CREBBP*        c.6127C\>T                 \+       Papathemeli et al. ([2015](#ajmga38603-bib-0039){ref-type="ref"})
  Pilomatricoma                         n/a     F     *EP300*         c.5153C\>T                 −        Negri et al. ([2015](#ajmga38603-bib-0038){ref-type="ref"})
  Pilomatricoma                         n/a     F     *EP300*         Microdeletion              −        Negri et al. ([2015](#ajmga38603-bib-0038){ref-type="ref"})
  Pilomatricoma (multiple)              n/a     F     *CREBBP*        c.4627G\>T                 −        Lopez‐Atalaya et al. ([2012](#ajmga38603-bib-0032){ref-type="ref"})
  Pilomatricoma                         n/a     F     *EP300*         c.1553_1554dup             −        Fergelot et al. ([2016](#ajmga38603-bib-0020){ref-type="ref"})
  Pilomatricoma                         n/a     F     *EP300*         c.4946G\>A                 \+       Fergelot et al. ([2016](#ajmga38603-bib-0020){ref-type="ref"})
  Pilomatricoma                         n/a     F     *EP300*         c.2113C\>T                 \+       Fergelot et al. ([2016](#ajmga38603-bib-0020){ref-type="ref"})
  Pilomatricoma                         n/a     M     *EP300*         c.4954_4957dup             −        Fergelot et al. ([2016](#ajmga38603-bib-0020){ref-type="ref"})
  Pilomatricoma                         n/a     F     *EP300*         c.1876C\>T                 \+       Fergelot et al. ([2016](#ajmga38603-bib-0020){ref-type="ref"})
  Pilomatricoma (multiple patients)     n/a     n/a   n/a             n/a                        n/a      Stevens et al. ([2011](#ajmga38603-bib-0057){ref-type="ref"})
  Pilomatricoma                         n/a     F     *CREBBP*        6122_6125del               n/a      Chiang et al. ([2009](#ajmga38603-bib-0016){ref-type="ref"})
  **Vascular**                                                                                            
  Angiofibroma                          5       M     n/a             n/a                        n/a      Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"})
  Angioma (cerebellum)                  n/a     F     n/a             n/a                        n/a      Thienpont et al. ([2010](#ajmga38603-bib-0059){ref-type="ref"})
  Soft tissue angioma                   n/a     M     EP300           Microdeletion 1‐31         n/a      Negri et al. ([2015](#ajmga38603-bib-0038){ref-type="ref"})
  Hamartoma (occipital)                 n/a     n/a   n/a             n/a                        n/a      Stevens et al. ([2011](#ajmga38603-bib-0057){ref-type="ref"})
  Hemangioma                            15      M     *CREBBP*        c.406C\>T                  −        Present study
  Hemangioma (capillary)                1       M     *CREBBP*        del(16)(p13.3p13.3)        n/a      Bartsch et al. ([1999](#ajmga38603-bib-0005){ref-type="ref"})
  Hemangioma (capillary)^i^             n/a     M     n/a             n/a                        n/a      Sahiner, Senel, Erkek, Karacan, and Yoney ([2009](#ajmga38603-bib-0050){ref-type="ref"})
  Hemangioma (capillary)                n/a     M     No deletion     n/a                        \+       Balci et al. ([2004](#ajmga38603-bib-0002){ref-type="ref"})
  Hemangioma (forehead)                 0       M     *CREBBP*        c.778C\>T                  n/a      Wincent et al. ([2016](#ajmga38603-bib-0069){ref-type="ref"})
  Hemangioma (forehead)                 n/a     F     *CREBBP*        Microdeletion              −        Lopez‐Atalaya et al. ([2012](#ajmga38603-bib-0032){ref-type="ref"})
  Hemangioma (frontal)                  0       F     n/a             n/a                        −        Candan, Ornek, and Candan ([2014](#ajmga38603-bib-0014){ref-type="ref"})
  Hemangioma (glabella)                 n/a     M     *CREBBP*        Microdeletion              n/a      Rusconi et al. ([2015](#ajmga38603-bib-0047){ref-type="ref"})
  Hemangioma (glabella)                 n/a     F     *CREBBP*        Microdeletion 4‐16         n/a      Rusconi et al. ([2015](#ajmga38603-bib-0047){ref-type="ref"})
  Hemangioma (hepatic)^i^               6       M     n/a             n/a                        n/a      Sahiner et al. ([2009](#ajmga38603-bib-0050){ref-type="ref"})
  Hemangioma (uvula)^b^                 41      F     *CREBBP*        c.1011dupA                 −        Present study
  **Other benign skin tumors**                                                                            
  Dermatofibroma^f^                     32      F     *CREBBP*        Microdeletion 9‐31         −        Present study
  Dermoid cyst eye                      6       F     n/a             n/a                        \+       Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"})
  Glomus tumor^m^                       n/a     M     n/a             n/a                        n/a      Siraganian et al. ([1989](#ajmga38603-bib-0054){ref-type="ref"})
  Lacrimal caruncle nevus               28      M     n/a             n/a                        n/a      Pogrzebielski, Piwowarczyk, Kohylarz, and Romanowska‐Dixon ([2007](#ajmga38603-bib-0042){ref-type="ref"})
  Naevus depigmentosus^g^               6       F     *CREBBP*        c.2199delG                 n/a      Yoo et al. ([2015](#ajmga38603-bib-0070){ref-type="ref"})
  Nevus                                 8       M     n/a             n/a                        n/a      Schepis, Greco, Siragusa, Batolo, and Romano ([2001](#ajmga38603-bib-0051){ref-type="ref"})
  Nevus^d^                              9       M     *CREBBP*        Exonic duplication 4‐23    n/a      Present study
  Nevus                                 21      F     n/a             n/a                        −        Present study
  Nevus^d^                              25      M     *CREBBP*        Exonic duplication 4‐23    n/a      Present study
  Nevus                                 40      F     n/a             n/a                        n/a      Present study
  Spitznevus                            20      F     n/a             n/a                        −        Present study

"a" to "m," Same individual having more than one tumor; Age, age at onset; n/a, data not available; M, male; F, female; ALL, acute lymphatic leukemia; AML, acute myeloblastic leukemia; MGSCST, malignant gonadal sex cord stromal tumor; NSCLC, non‐small cell lung carcinoma; DLBCL, diffuse large B‐cell lymphoma; HSIL, high‐grade squamous intra‐epithelial lesion of the cervix.

© 2018 Wiley Periodicals, Inc.

3.3. Genotype--phenotype correlation {#ajmga38603-sec-0010}
------------------------------------

In 51 of the 87 RSTS individuals in the present cohort, information on the germline variant in *CREBBP* (*n* = 42) or *EP300* (*n* = 3) was available. Variants could be classified as missense mutations leading to single amino acid alterations (*n* = 4), large deletions and duplications (*n* = 18), nonsense and frameshift mutations resulting in early truncation (*n* = 18), and splice site mutations (*n* = 5). In three patients, a germline variant in *CREBBP* (*n* = 1) and *EP300* (*n* = 2) was reported without further details and in eight patients no germline variant in either gene was found, despite a clinical diagnosis of RSTS.

Benign and malignant tumors were predominantly found in the large deletion/duplication group (19 tumors in 10/18 patients) and to a lesser extent in the groups with nonsense/frameshift mutations, (5 tumors in 4/14 patients), splice site mutations (3 tumors in 3/5 patients), and missense mutations groups (1 tumor in 4 patients). However, the effect of different variants on protein function is fully unpredictable, precluding any conclusions on specific associations and thus no clear genotype--phenotype correlations were observed in our series.

In the eight individuals without a detectable germline variant in *CREBBP* or *EP300*, no tumors were observed. There was no clear clustering of pathogenic variants in relation to tumors within the functional domains of CREBBP, and the variants are spread along the gene in the groups with and without tumors in similar ways (Figure [2](#ajmga38603-fig-0002){ref-type="fig"}).

![Variants in *CREBBP* in present cohort of individuals with RSTS with pilomatricoma, meningioma, intracranial malignancies, and other malignancies, compared to all CREBBP variants reported in LOVD. Various functional protein domains are indicated schematically. Individuals with a tumor from the present series of individuals with RSTS are indicated above the protein cartoon, individuals with RSTS reported in the LOVD are reported below the cartoon, each line or symbol representing a single individual. No specific distinction can be made between those with and without tumors in the latter series as this information is not known for all individuals. \[Color figure can be viewed at [wileyonlinelibrary.com](https://wileyonlinelibrary.com)\]](AJMG-176-597-g002){#ajmga38603-fig-0002}

The *CREBBP/EP300* mutation status was available in 28 RSTS individuals with a tumor reported in the literature, 10 missense mutations, 9 with truncating mutations, 7 with large deletions, 1 with a splice site mutation, and 1 with a translocation.

4. DISCUSSION {#ajmga38603-sec-0011}
=============

In this nation‐wide, population‐based cohort of 87 Dutch individuals with RSTS, the incidence of benign and malignant tumors was assessed. In Dutch individuals with RSTS, various malignant tumors were observed. Per age category, the incidence is compared to the general Dutch population (IKNL, [\[Link\]](#ajmga38603-bib-0023){ref-type="ref"}), but small numbers preclude formal epidemiological risk assessment (Figure [1](#ajmga38603-fig-0001){ref-type="fig"}). The overall frequency of malignancies in the presently reported Dutch RSTS population (8.3% in those with proven variants, 4.6% overall) is higher than previously reported by Siraganian and Miller (1.5% and 2.3%, respectively) (Miller & Rubinstein, [1995](#ajmga38603-bib-0036){ref-type="ref"}; Siraganian et al., [1989](#ajmga38603-bib-0054){ref-type="ref"}) in individuals with an age distribution similar to the present cohort. As the same definition for malignant tumors was used by the latter authors as by us, this may be caused by the opportunity in the Netherlands of using a comprehensive, population‐based, and nation‐wide search strategy. However, as PALGA has a nation‐wide coverage since 1989 only, the number of tumors may still be an underestimation, as tumors that have occurred before 1989 may have been missed.

In the present cohort, no single type of malignancy predominated. One individual with medulloblastoma and one individual with DLBCL were observed at (expected) ages of 9 and 57 years, respectively. In literature, five cases of medulloblastoma and 11 hematological malignancies have been reported at ages of 4--9 years and 0--58 years, respectively. The selection bias in the overview due to using case reports and non‐systematically gathered case‐series, prevents drawing any conclusions with respect to true frequencies of these tumors in individuals with RSTS or to associations between tumors and *CREBBP/EP300* variants.

Meningiomas were present in 8.3% of molecularly proven Dutch RSTS individuals (4.6% of all Dutch RSTS individuals) and occur in \<0.1% in the general Dutch population (Casparie et al., [2007](#ajmga38603-bib-0015){ref-type="ref"}; Wiemels, Wrensch, & Claus, [2010](#ajmga38603-bib-0067){ref-type="ref"}), supporting an increased risk to develop meningioma in RSTS individuals (Bourdeaut et al., [2014](#ajmga38603-bib-0009){ref-type="ref"}; Miller & Rubinstein, [1995](#ajmga38603-bib-0036){ref-type="ref"}; Skousen, Wardinsky, & Chenaille, [1996](#ajmga38603-bib-0055){ref-type="ref"}). This is further supported by presentation of two metachronous, independent meningiomas in a single individual in the present study, who has been reported before separately (Verstegen, van den Munckhof, Troost, & Bouma, [2005](#ajmga38603-bib-0064){ref-type="ref"}).

Pilomatricomas were found frequently (16.7% of molecularly proven and 9.2% of all individuals in the present study group; 0.16% histopathological diagnoses in general population in the same time interval (Casparie et al., [2007](#ajmga38603-bib-0015){ref-type="ref"}). Likely the incidence of pilomatricomas is even higher, since these are usually diagnosed on clinical grounds and only excised and submitted for histopathological examination when giving complaints. The same applies for naevi and other benign skin lesions. Though perhaps of little clinical importance, the association between RSTS and pilomatricoma remains intriguing, and may have a similar background as the increased frequency of keloids in individuals with RSTS (van de Kar et al., [2014](#ajmga38603-bib-0062){ref-type="ref"}). In the Dutch RSTS population, however, we have been unable to detect an association between their occurrences.

In the present cohort, genotype--phenotype correlation could be studied in 48 individuals for whom information regarding the *CREBBP* and *EP300* mutation status was available, and in literature similar data were available for 28 persons with RSTS. There was no obvious correlation between the incidence of tumors in general or specific tumor types with the location of variants within *CREBBP*. Tumors may be somewhat more common in individuals carrying large deletions as such deletions occur in 10% of RSTS individuals only (van Belzen, Bartsch, Lacombe, Peters, & Hennekam, [2011](#ajmga38603-bib-0061){ref-type="ref"}), but no firm conclusion is possible without data on much larger groups of RSTS individuals. A specific surveillance in children or adults with RSTS to detect tumors at an earlier age is not indicated based on presently available data.

In our cohort, we observed one patient with DLBCL (germinal center B‐cell \[GCB\]‐like subtype). Since somatic *CREBBP* mutation is a very frequent early event in follicular B‐cell lymphoma and diffuse large B‐cell lymphoma (Lohr et al., [2012](#ajmga38603-bib-0031){ref-type="ref"}; Morin et al., [2011](#ajmga38603-bib-0037){ref-type="ref"}; Pasqualucci et al., [2011](#ajmga38603-bib-0040){ref-type="ref"}; Zhang et al., [2011](#ajmga38603-bib-0072){ref-type="ref"}), this case was studied for somatic *CREBBP* alterations (Stevens et al., [2017](#ajmga38603-bib-0058){ref-type="ref"}). A somatic *CREBBP* mutation on one allele was found (His1438Asp, variant allele frequency \[VAF\] 25%), while the known germline mutation (*CREBBP* c.4837delG) was found in only 6% of sequence reads. These results should be interpreted as deletion of the germline mutated allele with an acquired, possibly subclonal alteration on the other allele in tumor cells. This may be suggestive of a tumor suppressor model for *CREBBP* in lymphoma.

Possible relations between somatic *CREBBP*/*EP300* mutations in other tumors have been implied. A biallelic deletion of CREBBP in medulloblastoma has been demonstrated (Bourdeaut et al., [2014](#ajmga38603-bib-0009){ref-type="ref"}), and somatic mutations have been detected in small numbers of breast and colon carcinomas well (Iyer, Ozdag, & Caldas, [2004](#ajmga38603-bib-0025){ref-type="ref"}). Linking CREBBP/EP300 to meningiomas and pilomatricomas would be very interesting, however to our knowledge, no literature to date is available regarding these tumors. More comprehensive research is required to study the possible role of *CREBBP* and *EP300* in oncogenesis.

Based on a nationwide, population‐based study, we conclude that RSTS individuals are at increased risk to develop meningiomas and pilomatricomas. An increased risk for malignant tumors could not be substantiated, but can also not be fully dismissed based on the small numbers of affected individuals both reported by us and in the literature and additional (international) studies are warranted. No genotype--phenotype correlation became evident. Based on the present data, a surveillance for specific tumors is not indicated in individuals with RSTS.
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